A phase I study of IMP321 and gemcitabine as the front-line therapy in patients with advanced pancreatic adenocarcinoma
about
From bench to bedside a comprehensive review of pancreatic cancer immunotherapy.Immune checkpoint inhibitors: therapeutic advances in melanomaAntibody Therapies in Cancer.Immune checkpoint inhibitors in clinical trialsThe role of checkpoints in the treatment of GBMCombined adjuvants of poly(I:C) plus LAG-3-Ig improve antitumor effects of tumor-specific T cells, preventing their exhaustion.Emerging targets in cancer immunotherapy: beyond CTLA-4 and PD-1.Trial Watch: Immunostimulatory monoclonal antibodies in cancer therapyClinical impact of checkpoint inhibitors as novel cancer therapies.On being less tolerant: enhanced cancer immunosurveillance enabled by targeting checkpoints and agonists of T cell activation.Emerging immune checkpoints for cancer therapy.Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation.T cell exhaustion: from pathophysiological basics to tumor immunotherapy.LAG3 (CD223) as a cancer immunotherapy target.Co-inhibitory blockade while preserving tolerance: checkpoint inhibitors for glioblastoma.Mechanistic and pharmacologic insights on immune checkpoint inhibitors.Overcoming the resistance of pancreatic cancer to immune checkpoint inhibitors.Newly Emerging Immune Checkpoints: Promises for Future Cancer Therapy.[Novel Immuno-oncology Therapy: Current Status of Clinical Research and Prospect of Application].Next generation of immune checkpoint therapy in cancer: new developments and challenges.Immunotherapies: Exploiting the Immune System for Cancer Treatment.Immunotherapy combination strategies (non-chemotherapy) in non-small cell lung cancer.Immune-checkpoint inhibitors for combating T-cell dysfunction in cancer
P2860
Q26765123-30A62845-F578-4BDB-BA72-8842E642E69FQ26775591-1C4B8F1B-0075-48EF-B71D-D6995FAF17BBQ31104000-2E9E0066-B7CC-4A4C-9C48-B2034276B659Q34309394-51EF5B49-F06B-4FC5-9BC0-8EF9FFDA8BE5Q36571197-B22E0F43-CF51-4AC9-BA49-9BCF8DC47891Q36801213-3639D1CF-2D52-44F5-BA03-AA52C31586BDQ37158481-CFFB65CF-8185-4E25-8B54-8C2CDF167CD4Q37652790-1B5FD6FD-DF93-4187-B596-5907F6E4C5FDQ38262593-B9B86FFE-CE48-433E-BC11-7CB609917003Q38391533-C0863EED-893A-4104-B37B-0C0A955E8F76Q38584979-5F1AFF17-4A56-424F-96AC-3A7DAE5FE40FQ38837469-42B1D3DF-397F-4A5A-957F-3683082521FBQ39078341-1256CE19-274F-4749-9E5D-4D13E35CBFF6Q39160974-C962E21F-5751-49D0-A724-5D55318902AAQ39160992-EEDB5943-17E1-4AC7-B830-10F40D9CFEEBQ39190066-C6EB3DC3-7505-444C-894D-068668165521Q39383207-9E6AE005-F4B1-43DA-9D2F-F1B84D28114CQ47301132-CC2B7471-1F7D-431E-BBC1-9CFDE10B8D46Q49958882-3797F369-880E-47A1-9610-C55677F0879BQ52653710-ADEC61DC-052F-44C9-9446-A38F9DD0084FQ55362851-1C6B0744-6E26-405B-BF1F-0FA91FD16525Q55503616-3B11FCB7-698F-45C4-B428-ED69CEC5B040Q57483931-CC3B201E-2887-466C-B97A-13105B61E0A4
P2860
A phase I study of IMP321 and gemcitabine as the front-line therapy in patients with advanced pancreatic adenocarcinoma
description
2012 nî lūn-bûn
@nan
2012 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
A phase I study of IMP321 and ...... nced pancreatic adenocarcinoma
@ast
A phase I study of IMP321 and ...... nced pancreatic adenocarcinoma
@en
type
label
A phase I study of IMP321 and ...... nced pancreatic adenocarcinoma
@ast
A phase I study of IMP321 and ...... nced pancreatic adenocarcinoma
@en
prefLabel
A phase I study of IMP321 and ...... nced pancreatic adenocarcinoma
@ast
A phase I study of IMP321 and ...... nced pancreatic adenocarcinoma
@en
P2093
P2860
P1476
A phase I study of IMP321 and ...... nced pancreatic adenocarcinoma
@en
P2093
Albert C Lockhart
Andrea Wang-Gillam
Benjamin Tan
Joel Picus
John R Hornick
Peter Goedegebuure
Peter O Simon
Rama Suresh
Stacey Plambeck-Suess
Steven Sorscher
P2860
P2888
P304
P356
10.1007/S10637-012-9866-Y
P577
2012-08-04T00:00:00Z
P6179
1030535488